Yuequan Shi

7PUBLICATIONS
12CO-AUTHORS
Cancer diagnosisPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical microbiology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 13, 2023
Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.

Haoran Zhang, Dongming Zhang, Jia Liu

|Jan 11, 2023
Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.

Qing Zhou, Xiangning Liu, Ji Li

|Dec 22, 2021
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.

Yuequan Shi, Jian Fang, Chengzhi Zhou

|Nov 26, 2021
Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy.

Yuequan Shi, Xiaoyan Liu, Juan Du

|Nov 11, 2021
Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response.

Yuequan Shi, Ji Li, Minjiang Chen

|Nov 01, 2018
Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.

Yuequan Shi, Mengzhao Wang

Pageof 2

Frequent Collaborators

5 joint publications

Minjiang Chen

5 joint publications

Yan Xu

1 joint publications

Jian Fang

1 joint publications

Chengzhi Zhou